PND12 LOWER DAILY AVERAGE CONSUMPTION AND GREATER PRESCRIPTION COST SAVINGS OF ARMODAFINIL COMPARED WITH MODAFINIL: A 12-MONTH RETROSPECTIVE DATABASE ANALYSIS  by Carlton, R. et al.
visits and inpatient care. The patternwas observed in each cohort. In two diseases:
sleep apnea- 29.6, no sleep apnea- 21.6. In three diseases: sleep apnea- 35.4, no
sleep apnea- 25.8. CONCLUSIONS: The more metabolic syndrome diseases the
higher risk for having OSA. The OSA burden is increasing the more metabolic
syndrome components exist.
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OBJECTIVES: Armodafinil and modafinil are indicated to improve wakefulness in
patientswith excessive sleepiness associatedwith treated obstructive sleep apnea,
shift work disorder, and narcolepsy. Because both medications are approved for
once-daily dosing with different tablet strengths, their real-world utilization may
differ. This analysis examined utilization of armodafinil and modafinil based on
daily average consumption (DACON) and determined the impact of armodafinil
and modafinil on pharmacy budgets using an economic modeling technique.
METHODS: DACON was examined in a retrospective database analysis of Wolt-
ers Kluwer Source LX pharmacy analytic data collected from March 1, 2009 to
May 31, 2010. DACON was calculated by dividing the total tablets dispensed by
the total days supplied. An economic model was used to evaluate the financial
impact of changes in prescription share from modafinil to armodafinil.
RESULTS: The DACON for armodafinil and modafinil were 1.03 (70,976 prescrip-
tions) and 1.40 (453,216 prescriptions), respectively. Among patients with 2 to 8
prescription fills for armodafinil, the DACON remained between 1.03 and 1.05. A
total of 6,069 modafinil patients switched to armodafinil. Their DACON on
modafinil was 1.46 before switching and was 1.05 after switching to armodafinil.
Based on economic modeling, and assuming a 10% increase in armodafinil’s share
of prescriptions, the projected annual cost savings with armodafinil would be
$921,949 (per-member-per-month savings of $0.077). Assuming a 20% increase in
armodafinil’s share, the projected annual savings would be $1,843,897 (per-mem-
ber-per-month savings of $0.154). CONCLUSIONS: By using pharmaceutical claims
data in tandem with well-designed economic models, payers can better estimate
current and future pharmaceutical spending. Based on this DACON analysis, the
utilization of armodafinil has a real-world advantage over modafinil that can sig-
nificantly affect pharmacy budgets. This researchwas sponsored by and conducted
in collaboration with Cephalon, Inc., Frazer, PA.
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OBJECTIVES: The objective of this retrospective claims database study was to bet-
ter understand the burden of illness for pediatric patients in the US who have
epilepsy with partial onset seizures and who are being treated with anti-epileptic
drugs (AEDs).METHODS:Datawere administrative claims from a large national US
health plan. Patients were commercial enrollees 2 years and 17 years of age
with 1 pharmacy claim for an oral AED from1/1/2006 – 11/30/2008; index datewas
defined as the first AED claim. Patients also had  1 medical claim for epilepsy
(ICD-9-CM 345.xx) during the 6 months pre-index period and were continuously
enrolled 12 months post-index. RESULTS: Within commercially insured pediatric
patients, 3,889 childrenmet inclusion criteria; 54%weremales; 59%were aged 2-11
years; and 51% lived in the southern US. Themean age of the population was 10.08
years. Overall, 77% had a Quan-Charlson comorbidity score of zero. Most fre-
quently reported AHRQ comorbid conditions included epilepsy convulsions (100%),
respiratory infections (66%), other nervous system disorders (43%) and headache
(20%). Of 8 epilepsy-related risk factors examined patients experienced hyperki-
netic syndrome (10%) and developmental disabilities (20%). Of 17 AEDmedications
examined, the most prescribed overall were: oxcarbazepine (OXC) 21%; levetirac-
etam (LEV) 19%; valporate (VPA) 17%; lamotrigine (LTG) 17%; with least prescribed
being gabapentin (GBP) at 1%. Their respective mean annual post-index pharmacy
and total costs were: $5441 and $11,430, LTG; $3025 and $9121, LEV; $2095 and
$5556, OXC; $1308 and $2807, VPA; and $917 and $1597, GBP. The overall post-index
mean annual pharmacy costs were $2637 andmean annual total costs were $6813.
CONCLUSIONS:Comorbid conditions associatedwith epilepsy are likely to contrib-
ute to the costs of pediatric epilepsy. Lamotrigine and Levetiracetam had the high-
est annual pharmacy costs compared to other drugs.
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OBJECTIVES: The objective of this retrospective claims database study was to bet-
ter understand the burden of illness for adults in the US who have epilepsy with
partial onset seizures and who are being treated with anti-epileptic drugs (AEDs).
METHODS: Data were administrative claims from a large national US health plan.
Patients were commercial enrollees18 years with 1 pharmacy claim for an oral
AED from 1/1/2006 – 11/30/2008; index date was defined as the first AED claim.
Patients also had  1 medical claim for epilepsy (ICD-9-CM 345.xx) during the 6
months pre-index period and were continuously enrolled 12 months post-index.
RESULTS:Within commercially insured adult patients, 9,889 adults met the study
inclusion criteria; 45%weremales; themean age was 43 years; and 49% lived in the
southern region of the US. Overall, 67% had a Quan-Charlson comorbidity score of
zero. Most frequently reported AHRQ comorbid conditions included: epilepsy con-
vulsions (100%), respiratory infections (42%), heart disease (36%) and headache
(31%). Of 8 epilepsy-related risk factors examined, patients most experienced de-
pression/mood disorders (12%), anxiety (8%), migraine (8%) and sleep disorders
(8%). Of 17 AED medications examined, the most prescribed overall were: leveti-
racetam (LEV) 19%; lamotrigine (LTG) 18%; phenytoin (PHT) 18%; carbamazepine
(CBZ) 14%, with the least prescribed being phenobarbital (PB) at 2%. Their respec-
tivemean annual post-index pharmacy and total costs were: $5169 and $6806, LTG;
$3788 and $6866, LEV; $1609 and $2564, CBZ; $1011 and $2409, PHT; and $245 and
$451, PB. The overall post-index mean annual pharmacy costs were $2736, and the
mean annual total costs were $4390. CONCLUSIONS: Epilepsy is a relatively com-
monneurological disorder associatedwith a range of comorbidities that impact the
medical management and the economic burden related to the disease.
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OBJECTIVES: Estimate the incremental costs associated with Alzheimer’s Disease
(AD). The incremental impact of AD on Medicaid costs has not been updated since
1995 and the impact of AD on other payers is unclear.METHODS: Patients age 50
were identified from de-identified Medicaid paid claims from California [MediCal].
All patients were MediCal eligible for the period 2004-2006 [survivors]. Data in-
cluded information on payments by MediCal, Medicare and other payers. AD pa-
tients had at least one AD diagnosis. A 20% random sample of non-AD patients was
selected and a matched control group was identified using propensity score meth-
ods. Health care cost and resource utilization were measured annually during the
2004-2006 period broken down by type of service and payer. Multivariate statistical
models were estimated to document the incremental impact of AD controlling for
baseline characteristics of the matched AD and non-AD patients. RESULTS: The
incremental cost of AD relative to non-AD patients increased from$7,217 in 2004
to$15,563 in 2006, totaling$34,745 over 3 years. Themajority of the cost burden
is bourn by MediCal [$30,090] primarily for nursing home care [$15,498], home
health care [$9,146] and prescription drugs [$3,938]. The incremental cost of AD
on Medicare and other payers [including out-of-pocket costs] were $2,814 and
$1,842, respectively [p0.0001 for all estimates].CONCLUSIONS:The incremental
impact of AD on the health care system is significant. The increased costs attrib-
uted to AD in this analysis are due primarily to higher costs for nursing home care
and home health services. New AD medications currently under development, if
effective, will benefit Medicaid programs but be paid for largely by Medicare under
Part D. This study provides useful information on the potential benefits that could
accrue due to an effective AD treatment and documents how these benefits will be
distributed by payer.
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OBJECTIVES: To examine hemophilia-related healthcare costs among persons
with hemophilia A at six US Hemophilia Treatment Centers (HTCs). METHODS:
Data on 315 persons aged 2-65 years from seven states enrolled in Hemophilia
Utilization Group Study (HUGS-Va, 2005-2007) were obtained prospectively from
interviews and chart reviews. One-year healthcare utilization data (HTC visits,
laboratory tests, outpatient visits, emergency room (ER) visits, hospitalizations)
and units of clotting factor dispensed were used to impute costs. HTC visit and
laboratory test expenditures were obtained from Medicare payment schedules.
Inpatient costs were estimated using ICD-9 codes and HCUP National Inpatient
Sample charges adjusted for cost-to-charge ratio from MedPAR. ER costs were es-
timated using MEPS data. Factor costs were estimated using Medicare Part B reim-
bursement rates. Per-unit prices for non-factor medications were estimated using
wholesale acquisition costs. All costs were converted to 2010 US dollars. Socio-
demographic and clinical characteristics associated with higher costs were ana-
lyzed using a multivariate model. RESULTS: Fifty-one percent of participants were
adults; mean age was 21.2(14.8) years. Two-thirds had severe hemophilia. 94%
used clotting factor; 64% of severe patients infused prophylactically. Annual mean
healthcare costs per patient (excluding medication) were $3,912(9,267),
$3,975(8,422), $16,185(46,097) and $2,852(7,721), respectively, for patients with
mild,moderate, severe hemophilia on episodic treatment, or severe hemophilia on
prophylactic treatment. Annual hemophilia-relatedmedication costs for the same
groupswere $42,377(115,246,median:$3,573), $63,063(113,571,median:$22,587),
$159,830(143,220,median:$113,263) and $275,376(178,573,median:$246,333), re-
spectively (P0.0001). Inhibitor patients (N16) had healthcare and medication
costs of $13,086(19,163,median:$2,223) and $721,603(914,069,median:$199,319),
respectively. Older age, higher weight, greater hemophilic severity, with insurance
coverage, prophylaxis treatment, and positive inhibitor were associated with
higher total costs. CONCLUSIONS: Hemophilia is a costly disorder. This data pro-
vides information on annual healthcare and factor costs associated with hemo-
philia. Identifying factors associatedwith increased healthcare utilization and out-
comes will advance our understanding of the economic impact of this condition.
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